The brokerage incorporates Ajanta Pharma's quarterly performance into its estimates and expect India to remain a key growth driver, supported by sustained outperformance against IPM, while factoring in normalisation in Africa institutional business.
The brokerage incorporates Ajanta Pharma's quarterly performance into its estimates and expect India to remain a key growth driver, supported by sustained outperformance against IPM, while factoring in normalisation in Africa institutional business.
<iframe src="https://hindustansphere.com/embed/cluster/b5feccce55eae9eef45c6b3eaddeade59dd7a195" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Ajanta Pharma Q2 Review: Stock Rally Limits Upside Despite Robust Performance, Says Systematix"></iframe>
